A Single Infusion Could Replace Decades of Daily Cholesterol Pills
Sandego.net – For most adults living with elevated LDL cholesterol, the prescription pad ends with a familiar instruction: take one tablet every morning, indefinitely. Now a small but striking clinical result suggests that future patients with severe, drug-resistant hyperlipidemia might instead receive a single intravenous infusion and walk away with a permanently altered lipid profile. Scientists disclosed that a one-time CRISPR-Cas9 edit of a specific liver gene cut low-density lipoprotein cholesterol by roughly half over a full year, with no observed adverse events in the highest-dose cohort.
The data come from a pilot trial of just 15 individuals whose cholesterol levels had proven stubbornly resistant to conventional pharmacotherapy. Four of those participants received the maximum dose of the experimental gene-altering infusion. Their follow-up results, detailed in an update published in The New England Journal of Medicine on Friday, confirm that the lipid-lowering effect seen at 60 days persisted through the 12-month mark without safety signals.
“Is something like this truly a one and done? That was always the question,” said lead study author Dr. Luke Laffin, a preventive cardiologist at Cleveland Clinic’s Heart, Vascular & Thoracic Institute. “This new data is essentially saying that the decreases in LDL cholesterol and triglycerides we saw at 60 days after treatment have lasted over a year. In people who took the highest dose, the reduction seems durable and safe.”
The Biological Rationale: Mimicking a Protective Mutation
The therapeutic concept traces back to a naturally occurring genetic variant in the ANGPTL3 gene — angiopoietin-like protein 3 — which normally helps regulate both LDL and triglyceride levels. Approximately one in 250 Americans carries a loss-of-function mutation in one or both copies of this gene. Those individuals enjoy profoundly low circulating LDL and triglyceride concentrations throughout their lives, with no apparent downside, and face a sharply reduced lifetime risk of cardiovascular events.
Senior study author Dr. Steven Nissen, who holds the Lewis and Patricia Dickey Chair in Cardiovascular Medicine and serves as chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Ohio, framed the logic plainly:
“It’s a naturally occurring mutation that’s protective against cardiovascular disease,” Nissen said. “And now that CRISPR is here, we have the ability to change other people’s genes so they too can have this protection.”
Unlike the natural mutation, which silences ANGPTL3 in every cell of the body, the CRISPR-Cas9 therapy is engineered to act exclusively in hepatocytes — the liver cells responsible for synthesizing triglycerides, manufacturing cholesterol, and clearing excess lipids from circulation. That organ-specific targeting, Nissen noted, reduces the probability of unintended edits elsewhere and bolsters the long-term safety profile of the intervention.
Study Design and Dose Escalation
The pilot trial, first reported in November 2025, was structured as a first-in-human safety assessment. Fifteen patients with very high, medication-refractory cholesterol received one of five escalating doses of the CRISPR-based infusion, ranging from 0.1 milligrams per kilogram of body weight up to the maximum level. The primary endpoint was safety; lipid changes were tracked as secondary outcomes. The four participants at the top dose produced the most pronounced and sustained reductions in both LDL and triglycerides.
Nissen, reflecting on how far the field has traveled, offered a candid retrospective:
“If you’d asked me 15 years ago if we could have done something like this, I would have thought you were crazy.”
Why a One-Time Fix Matters Beyond the Lab
Heart disease remains the leading cause of death among adults in the United States and across most of the world. LDL cholesterol is a central driver of atherosclerotic plaque formation, while elevated triglycerides independently raise cardiovascular risk. Yet even with multiple approved drug classes on the market, adherence remains a persistent weakness. Researchers estimate that only about half of patients take their cholesterol medication more than 80 percent of the time, and between one-third and one-half of statin users stop taking the drug within the first year of therapy.
Dr. Ann Marie Navar, an associate professor of cardiology at UT Southwestern Medical Center in Dallas who was not involved in the trial, emphasized the practical stakes for younger patients facing decades of daily dosing:
“If you’re 20 and you have really high cholesterol, it may make a lot more sense to have a one-time treatment that doesn’t require you to have to take a pill every single day or shot every two weeks for the next 60 years,” Navar said. “The potential for this is just enormous.”
She added that the sheer volume of uncontrolled LDL across all age groups, despite the availability of effective therapies, makes a durable, single-administration approach particularly compelling from a public-health standpoint.
What Comes Next
The pilot data answer a narrow but critical question — durability and short-term safety at the highest dose — while leaving the larger efficacy-and-safety picture unresolved. Larger, randomized trials will need to confirm that the lipid-lowering magnitude holds across diverse populations, that off-target genomic edits remain negligible over years of follow-up, and that cardiovascular event rates actually decline. If those trials replicate the pilot findings, a single infusion could reshape the treatment paradigm for familial and other forms of severe hyperlipidemia, shifting the burden from lifelong daily compliance to a one-time procedural intervention performed in a monitored clinical setting.
Until then, the result stands as a proof of concept: a molecular scissors, guided to a single gene in a single organ, can rewrite a patient’s lipid trajectory for the rest of their life — at least, so far, without measurable cost.
Related Reading
Frequently Asked Questions
What is With the snip of a gene?
With the snip of a gene is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does With the snip of a gene matter?
With the snip of a gene matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.
